Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation

BACKGROUND: Erythropoietin-stimulating agents (ESAs) effectively decrease the transfusion requirements of patients with chemotherapy-induced anaemia (CIA). Recent studies indicate that ESAs increase mortality and accelerate tumour progression. The studies also identify a 1.6-fold increased risk of v...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujisaka, Y, Sugiyama, T, Saito, H, Nagase, S, Kudoh, S, Endo, M, Sakai, H, Ohashi, Y, Saijo, N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241560/
https://www.ncbi.nlm.nih.gov/pubmed/21959870
http://dx.doi.org/10.1038/bjc.2011.395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241560/
https://www.ncbi.nlm.nih.gov/pubmed/21959870
http://dx.doi.org/10.1038/bjc.2011.395

Ejemplares similares